| |
| |
|
 |
 | | 21.08.2008 | | TIME: 17:07:39 | | LAST | 8,65 € | | OPEN | 8,67 € | | CHANGE | +0,23% |
|
|
 |
|
|
|
| |
|
| |
| The ThromboGenics Board is composed of experienced people
from different disciplines and with a broad view on the Life Sciences
industry. The executive members are Désiré Collen, Chairman and
founder of ThromboGenics and Chris Buyse, CFO. The nonexecutive members are Landon T. Clay, Manager Member of East
Hill Advisors, LLCC and partner of East Hill University Spinout Funds; Jean-Luc Dehaene, former prime minister of Belgium and
vice-chairman of the European Convention; Luc Philips, Chairman of KBC Insurances and director
of Kredietbank NV; Staf van Reet, Chairman of Movetis. |
 |
Dr
D. Collen, MD, PhD I Chairman and founder of ThromboGenics
 |
Désiré Collen holds a MD degree and PhD degree in Chemistry from the University of Leuven, Belgium. Founder of ThromboGenics, he is
currently Director of the Center for Molecular and Vascular Biology of the KULeuven, and the Center for Transgene Technology and
Gene Therapy of the Flanders Interuniversity Institute for Biotechnology in Leuven, Belgium.
He has received four honorary doctorates and several scientific awards including the Francqui Prize
(Belgium). His team discovered and initially developed tPA, currently the most effective drug for thrombolytic
therapy of acute myocardial infarction. Prof. Collen is a Non-Executive Director of Beta Cell NV. I top |
|
 |
Chris
Buyse I Chief Financial Officer
| Chris Buyse brings to ThromboGenics 20 years experience in international company finance and in running and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign where he coordinated its acquisition by BASF in early 2007. Before this, Mr. Buyse was Finance Director of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecom companies, and was CFO and interim CEO of Keyware Technologies, reporting to the President of the Board. In addition, he held several financial positions as financial controller and internal auditor at Spector Photo Group, Suez Lyonnaise des Eaux and Unilever. I top |
 |
|
 |
Landon
T. Clay I Non-Executive
Director
 |
Mr. Clay is a Managing Member of East Hill Advisors, LLC, the general
partner of East Hill University Spinouts Funds. Prior to co-founding
East Hill, he was chairman and chief executive officer (CEO) of Eaton
Vance Corporation, an investment management firm listed on the NYSE.
He is chairman of the Clay Mathematics Institute, which he founded
in 1998, ADE Corporation and the Caribbean Conservation Corporation
and is a director of Golden Queen Mining Co. Ltd. He has served on
the board of the Museum of Fine Arts, Boston, Middlesex School, Concord,
MA, and the Smithsonian Institution, Washington, DC. Mr Clay received
an AB, cum laude, from Harvard College and served as an Overseer of
Harvard from 1975 to 1981. He has donated Professorships in Mathematics
and in Scientific Archaeology at Harvard and financed Harvard’s
share in the construction of the Magellan Telescope in Chile. He has
also given smaller observational telescopes to Dexter School and Middlesex
School. I top |
|
 |
Jean-Luc
Dehaene I Non-Executive
Director
| Mr. Jean-Luc Dehaene has occupied several ministerial posts. He was
Prime Minister of Belgium from 1992 until 1999 and vice-chairman of
the European Convention. He is a member of the board of directors of
Umicore NV, Inbev NV, Telindus Group NV, Domo NV and Lotus Bakeries
NV. He is chairman of the board of directors of College of Europe (Bruges).
He is member of the European Parliament and mayor of Vilvoorde. Mr.
Dehaene studied law and political and social sciences in Namur and
Leuven, Belgium. I top |
 |
|
 |
Luc
Philips I Non-Executive
Director
 |
Mr. Philips has a degree in commercial and financial sciences from
the Hoger Instituut voor Bestuurs- en Handelswetenschappen (HIBH) in
Brussels. In 1997, he was appointed to the board of directors and the
executive committee of Kredietbank. From 1998 to 2003, he was managing
director of the KBC Bank and Insurance Holding Company and KBC Bank.
He was appointed managing director of Almanij in 2003. In the same
year, he was also appointed director of the KBC Bank and Insurance
Holding Company, KBC Bank, KBC Insurance and KBL, and became chairman
of the audit committee of the first three of these companies. After
the merger of KBC Bank and Insurance Holding Company and Almanij, Luc
Philips remained chairman of the audit committee of KBC Group NV and
KBC Bank, joined the audit committee of KBC Insurance, and became chairman
of the board of directors of KBC Insurance and deputy
chairman of the board of directors of KBC Bank. Furthermore, he serves
on various boards of directors of companies that are part of KBC Group
NV, of which two are active in Central Europe (K&H Bank in Hungary
and Kredyt Bank in Poland). Luc Philips is also a member of the board
of directors of Norkom Technologies (Ireland) en of Gemma Frisius Fonds
(Belgium). I top |
|
 |
Staf
Van Reet, Ir. Ph.D I Non-Executive
Director
| Dr Van Reet is
chairman of FlandersBio
VZW and managing
director of Viziphar
Biosciences BVBA,
a start-up bio-pharma
research and development
company, and its
subsidiary Viziphar
Biosciences PVT Ltd
(Bangalore, India)
of which he is also
chairman of the board
of directors. He
serves on various
other boards including
Janssen Pharmaceutica
NV, the Flanders
Interuniversity Institute
for Biotechnology
(VIB), the Antwerp
Incubation Center
NV (AIC), 4AZA Bioscience
NV and Vivactis NV.
Dr Van Reet joined Janssen
Pharmaceutica, an
affiliate of Johnson & Johnson,
in 1972 as a scientist
in the Department
of Theoretical Medicinal
Chemistry. In 1973
he moved to the Department
of Patents and Pharmacochemical
Data Processing,
which he headed from
1977 to 1989. Since
1987 he took increasingly
important general
management responsibilities
as managing director
of Janssen Biotech,
chairman of the management
board of the Janssen
Research Foundation
and from 1991 to
1999 as president
of the Janssen Research
Foundation and managing
director of Janssen
Pharmaceutica NV.
From 2000 until 2004
Dr Van Reet was vice
president of Johnson & Johnson
Development Corporation,
the venturing arm
of Johnson & Johnson,
and from April until
June 2005 he was
a member of the management
committee of Galapagos
NV. Dr Van Reet holds
a degree of engineering
in Applied Biological
Sciences and a Ph.D.
in Agricultural Sciences
from the University
of Leuven, Belgium
and studied law at
the University of
Antwerp. He is a
qualified Belgian
and European Patent
Authority. I top |
 |
|
|
|
| |
All rights reserved © Thrombogenic 2006 Last update:
April 14, 2008
Inspired by Echo |
|
|